Other studies have found that some indicators in the ccRCC microenvironment, such as CD8+T-cell density and PD-1/PD-L1 expression in the tumor and invasive margin (8), can be used as indicators to evaluate the clinical effectiveness of PD-1 inhibitors (9, 10). This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.